Molecular Cancer Therapeutics

OCT 8, 2026 · JOURNAL ARTICLE

Targeting YAP/TEAD signaling disturbs RNA Pol II activity and enhances immunotherapy response via activated cytosolic DNA sensing pathway in gastroesophageal cancer

Molecular Cancer Therapeutics

Abstract Gastroesophageal adenocarcinoma (GEAC) is a significant global cancer burden. Our previous studies demonstrated that YAP/TEAD are highly expressed in GEAC, and play a crit

OCT 8, 2026 · JOURNAL ARTICLE

PLK1 inhibition by onvansertib enhances paclitaxel efficacy and overcomes resistance in HR+/HER2- breast cancer refractory to endocrine therapy and CDK4/6 inhibitors

Molecular Cancer Therapeutics

Abstract Hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer that progresses on CDK4/6 inhibitors (CDK4/6i) and endocrine therapy (ET) faces a major therapeutic

SEP 24, 2026 · JOURNAL ARTICLE

Inhibition of PLK1 helps to restrict c-Met-induced growth and therapeutic resistance of renal cancer cells

Molecular Cancer Therapeutics

Abstract Acquired therapeutic resistance is a major problem in the treatment of advanced renal cell carcinoma (RCC). The receptor tyrosine kinase (RTK) c-Met is hyperactive in RCC

AUG 13, 2026 · JOURNAL ARTICLE

Sensitivity of pancreatic adenocarcinoma cells to blockade of post-initiation CDK-dependent Pol II transcription cycle checkpoints

Molecular Cancer Therapeutics

Early-phase cell line study profiling molecular responses to kinase inhibitors; identifies potential vulnerabilities but lacks human efficacy data, animal validation, or clinical endpoints needed to guide practice.